Micro-Caps — page 11
Lineage Chose Animal Testing for New Corneal Cell Therapy
The biotechnology developer reported $4.8 million in quarterly research spending as its new COR1 eye-disease program cleared internal criteria for further preclinical work.
Korro Bio Adds Drug Candidate for Genetic Liver and Lung Disease
The RNA-editing drug developer ended June with $137.9 million in cash and securities, which it expects to fund operations into the second half of 2028.
Friedman Posts Record Volume and Lifts Earnings
Net earnings reached $12.8 million, or $1.79 a share, on sales of $240.0 million as volume hit about 206,000 tons.
Expensify Lifts Full-Year Free Cash Flow Outlook
The company now estimates $12.0 million to $14.0 million of free cash flow for the year ending December 31, 2026, after a $6.4 million second-quarter print.
Precision BioSciences Reports First Biopsy Proof of cccDNA Elimination
Liver biopsies in ELIMINATE-B showed a 1-log cccDNA drop with under 1% remaining after two PBGENE-HBV doses, and cash stood at $112.4 million at June 30.
Cerence Authorizes First Share Repurchase Program
The board approved up to $30 million of buybacks as third-quarter revenue reached $69.6 million and Adjusted EBITDA rose 50% to $13.5 million.
Corbus Wins FDA Clearance for CRB-701 Phase 3 Trial
Cash of $117.9 million is expected to fund operations into 2028 as the company prepares two September clinical milestones.
Commerce.com's Revenue Growth Stalls After First-Quarter Rebound
Second-quarter revenue was $84.5 million, up 0.1% from a year earlier, after 5% growth in the first quarter, as subscription solutions turned negative.
Citizens Swings to a Loss as Endowment Maturities Recede
Direct insurance premiums reached $48.1 million in the second quarter, the fifteenth straight year-over-year gain in first-year premium.
Blend Labs Growth Cools After a Faster First Quarter
Second-quarter revenue was $33.8 million, up 7% from a year earlier, as non-GAAP operating income reached $7.0 million.
ALX Oncology Cash Reaches $153.4 Million After Refinancing
The clinical-stage biotech said cash, cash equivalents and investments of $153.4 million as of June 30, 2026, are sufficient to fund planned operations through the first half of 2028.
Alta Equipment Tightens 2026 Adjusted EBITDA Range
The equipment dealer now expects full-year Adjusted EBITDA of $167.5 million to $177.5 million after second-quarter Adjusted EBITDA of $48.6 million.
Market Gains Mask Asset Managers’ Flow Strain
Asset appreciation lifted AUM across major managers, while persistent redemptions and slower fundraising exposed weaker underlying growth.
Xperi Keeps 2026 Outlook After Advertising Growth
Advertising and related revenue reached $14.98 million in the second quarter, up 54% from a year earlier, as TiVo One monthly active users hit 6.3 million.
Weight Watchers Restores Profit After Peak-Season Marketing Reset
Second-quarter revenue was $162.3 million as Clinical Subscription Revenue reached $39.9 million and Adjusted EBITDA swung to $39.8 million.
Vanda Reiterates 2026 Revenue Guidance After Fanapt Sales
Second-quarter total net product sales were $50.5 million, excluding about $7.0 million of HETLIOZ orders to be booked in the third quarter.
Entrada Completes ELEVATE-45 Cohort 1 and Starts 10 mg/kg Dosing
Cash, cash equivalents and marketable securities were $223.0 million as of June 30, 2026, and the company said the balance will fund operations into the third quarter of 2027.
TriplePoint Venture Growth Restarts Supplemental Distributions
The board declared a $0.23 regular payout plus $0.12 of supplemental distributions after a $12.8 million Revolut sale lifted net assets to $0.26 a share.
Stoneridge Reaffirms 2026 Outlook After Record Adjusted Ebitda
Adjusted EBITDA was $5.5 million, or 3.0% of sales, versus $0.8 million a year earlier, as the company kept its $645 million to $670 million revenue range.
SmartRent Restores Core Revenue Growth After a Flat First Quarter
Core revenue reached $38.4 million, up 14% from a year earlier, and Adjusted EBITDA was $0.7 million as the company posted a third straight quarter of positive Adjusted EBITDA.
Seaport Entertainment Posts First Adjusted Profit in Two Years
Non-GAAP adjusted net income attributable to common stockholders was $0.32 million, or $0.02 a share, after a $17.88 million adjusted loss in the first quarter.
RGC Resources' Summer Margin Gain Is Wiped Out by Costs
Operating margin rose $757,000 year over year in the June quarter, but expenses rose by a similar amount and diluted earnings stayed at $0.05 a share.
Portillo's Cuts Corporate Workforce After Same-Sales Slide
Same-restaurant sales fell 1.2% in the second quarter as transactions dropped 3.4% and commodity prices rose 7.0%.
Palmer Square Narrows Mark Losses After a Heavy First Quarter
Net investment income was $12.0 million, or $0.39 a share, as the company declared a $0.36 third-quarter base dividend.
OraSure Core Sales Hold After Two-Quarter Slide
Second-quarter revenue of $30.6 million rose 9.7% from the prior quarter and sat above the company's guidance range.
Oportun Raises Full-Year Ebitda Outlook After Margin Expansion
Adjusted EBITDA reached $49 million in the second quarter, and the company lifted its full-year range 6% at the midpoint to $160 million to $175 million.
Orion Raises Free Cash Flow Outlook After Specialty Rebound
Second-quarter Adjusted EBITDA reached $58 million, and the company lifted its 2026 free cash flow range to a $10 million outflow to $20 million inflow.
Lightbridge Removes First Irradiated Fuel Samples From Reactor
Cash and cash equivalents were $237.5 million at June 30, 2026, as Lightbridge posted a $5.8 million net loss for the quarter.
LifeMD Cuts 2026 Profit Outlook After GLP-1 Shift
Second-quarter revenue was $47.3 million and the company now sees full-year adjusted EBITDA of negative $6.0 million to breakeven.
CS Disco Raises Low End of 2026 Revenue Outlook
Second-quarter revenue was $43.1 million, up 13% from a year earlier, as the company lifted the low end of its full-year total-revenue range.